Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RAPP is 17.46M, and currently, short sellers hold a 10.36% ratio of that float. The average trading volume of RAPP on March 13, 2025 was 169.16K shares.
RAPP) stock’s latest price update
Rapport Therapeutics Inc (NASDAQ: RAPP) has experienced a rise in its stock price by 11.72 compared to its previous closing price of 8.96. However, the company has seen a fall of -4.39% in its stock price over the last five trading days. globenewswire.com reported 2025-03-11 that Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219’s transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025 Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027 Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer Ended the year with $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter and full year ended December 31, 2024, and provided a business update.
RAPP’s Market Performance
RAPP’s stock has fallen by -4.39% in the past week, with a monthly drop of -39.07% and a quarterly drop of -51.08%. The volatility ratio for the week is 17.47% while the volatility levels for the last 30 days are 16.13% for Rapport Therapeutics Inc The simple moving average for the past 20 days is -12.78% for RAPP’s stock, with a -49.81% simple moving average for the past 200 days.
Analysts’ Opinion of RAPP
Stifel, on the other hand, stated in their research note that they expect to see RAPP reach a price target of $35. The rating they have provided for RAPP stocks is “Buy” according to the report published on July 02nd, 2024.
Jefferies gave a rating of “Buy” to RAPP, setting the target price at $35 in the report published on July 02nd of the previous year.
RAPP Trading at -28.93% from the 50-Day Moving Average
After a stumble in the market that brought RAPP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.34% of loss for the given period.
Volatility was left at 16.13%, however, over the last 30 days, the volatility rate increased by 17.47%, as shares sank -36.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.08% lower at present.
During the last 5 trading sessions, RAPP fell by -4.39%, in comparison to the 20-day moving average, which settled at $11.48. In addition, Rapport Therapeutics Inc saw -43.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPP starting from HEALY JAMES, who purchase 44,032 shares at the price of $24.52 back on Jul 01 ’24. After this action, HEALY JAMES now owns 40,851 shares of Rapport Therapeutics Inc, valued at $1,079,575 using the latest closing price.
HEALY JAMES, the Director of Rapport Therapeutics Inc, purchase 558,824 shares at $17.00 during a trade that took place back on Jun 10 ’24, which means that HEALY JAMES is holding 1,863,327 shares at $9,500,008 based on the most recent closing price.
Stock Fundamentals for RAPP
The total capital return value is set at -0.23.
Based on Rapport Therapeutics Inc (RAPP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.79.
Currently, EBITDA for the company is -83.06 million with net debt to EBITDA at 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 45.91.
Conclusion
To put it simply, Rapport Therapeutics Inc (RAPP) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
